ORYZON Announces Publication of a relevant paper for the therapeutic development of Iadademstat (ORY-1001) in Small Cell Lung Cancer (SCLC)

by Oryzon Genomics

Complete and durable tumor regression occurred with Iadademstat–induced NOTCH activation in a chemoresistant PDX model. Further supports LSD1 inhibitors as a possible new and targeted therapy for SC...

Read more

An international clinical trial extends the effectiveness of immunotherapy to more lung cancer patients

by CNIO - Centro Nacional de Investigaciones Oncológicas

Combining immunotherapy with chemotherapy in patients with metastatic squamous cell carcinoma "significantly increases" the survival of patients, write the authors in The New England Journal of Medici...

Read more

Oryzon receives approval to start CLEPSIDRA: a Phase IIa clinical trial in Small Cell Lung Cancer with Iadademstat (ORY-1001)

by Oryzon Genomics

The study, named CLEPSIDRA, will be conducted in several Spanish hospitals . CLEPSIDRA is a single - arm, open - label study of Iadademstat in combination with the standard of care treatment p latinum...

Read more

Inactivation of the B2M gene is recurrent in lung cancer and may condition the response to immunotherapy

by IBEC - Institut de Bioenginyeria de Catalunya

Researchers from the Genes and Cancer research group at the Bellvitge Biomedical Research Institute (IDIBELL) have identified inactivating mutations in a number of genes that code for HLA-I histocompa...

Read more

Bronchial GPS helps in early detection of lung cancer

by Universitat Autònoma de Barcelona (UAB)

Researchers from the UAB, the CVC and the Hospital de Bellvitge - Idibell have developed a technology for biopsies which can navigate through a patient's airways following a ready-planned and localise...

Read more

Palobiofarma receives milestone payment from Novartis

by Palobiofarma

The milestone payment is the first from the licensing agreement between the two companies. Under the terms of that agreement, which was signed in September 2015, Novartis has exclusive development and...

Read more

Scientists prove the effectiveness of a new combination of drugs in a type of incurable lung cancer

by IBEC - Institut de Bioenginyeria de Catalunya

Researchers at the Bellvitge Biomedical Research Institute (IDIBELL), led by Dr. Montse Sanchez-Cespedes, have demonstrated in in vitro and in vivo studies the effectiveness of a new drug combination ...

Read more

Ability Pharmaceuticals enters into a licensing agreement with SciClone Pharmaceuticals for the novel anticancer agent ABTL0812 for the China market

by Ability Pharma

Collaboration boosts development of a fully differentiated inhibitor of the PI3K/Akt/mTOR pathway. ABTL0812 is currently in Phase 2 clinical trials to treat lung and endometrial cancers.

Read more

Researchers at CIMA have identified a biomarker which offers prognosis after lung cancer surgery

by CIMA - Centro de Investigación Médica Aplicada

The research work led by CIMA has identified a molecule, called TMPRSS4, which acts as a biomarker for the prognosis of lung cancer. "By means of complex technological systems called "microarrays" and...

Read more

CNIO researchers find a potential therapy for the most aggressive type of lung cancer in preclinical models

by CNIO - Centro Nacional de Investigaciones Oncológicas

The specific combination of the drugs dasatinib and demcizumab impairs the growth of KRAS-driven lung tumours, the most aggressive sub-type and with the lowest survival rates

Read more

Public-private research: the University of Barcelona (UB) and the Hospital Clínic collaborate with Boehringer Ingelheim

by Fundació Bosch i Gimpera

This study goes a step further and investigates nintedanib* effectiveness in squamous cell carcinoma, so it will use new preclinical cell crops models, unique in Spain, that allow interaction between ...

Read more

Palobiofarma signs licensing agreement to develop novel adenosine-based immuno-oncology treatments

by Palobiofarma

Under the terms of the agreement Novartis will acquire exclusive global rights to develop, manufacture and commercialize Palobiofarma´s adenosine A2Areceptor antagonist PBF-509, currently entering Ph...

Read more
Subscribe to Directory
Write an Article

Recent News

El diagnóstico genético neonatal mejor...

Un estudio con datos de los últimos 35 años, ind...

Más de 1.500 cambios epigenéticos en e...

Un equipo de investigadores de la Universidad Juli...

Tuneable reverse photochromes in the sol...

A new technique allows the design of solid materia...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

Un estudio de INCLIVA muestra el efecto ...

by INCLIVA

Han desarrollado un estudio para evaluar la correlación entre el teji...

Photos Stream